1月27日 - ** 药物开发商卡迪夫肿瘤CRDF.O股价盘前下跌32%至2美元
** 卡迪夫首席执行官和首席财务官双双卸任 (link)，立即生效
** 该公司称，董事会成员莫欣德鲁（Mani Mohindru）被任命为临时首席执行官，同时正在寻找替代人选。
** 另外，CRDF称，一项中期试验显示，在标准一线化疗方案中加入其实验性药物onvansertib可提高应答率 (link) 并延缓难以治疗的结直肠癌患者的疾病进展。
** 称在接受标准化疗的同时接受30毫克高剂量onvansertib治疗的患者的应答率为72%，而单独接受标准治疗的患者的应答率为43%。
** 补充说，该公司计划在今年晚些时候启动一项规模更大的后期试验
** 2025年，CRDF下降了34%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.